<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35294901</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>23</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1097-4199</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>110</Volume>
            <Issue>10</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>18</Day>
            </PubDate>
          </JournalIssue>
          <Title>Neuron</Title>
          <ISOAbbreviation>Neuron</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Loss of mouse Stmn2 function causes motor neuropathy.</ArticleTitle>
        <Pagination>
          <StartPage>1671</StartPage>
          <EndPage>1688.e6</EndPage>
          <MedlinePgn>1671-1688.e6</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2022.02.011</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0896-6273(22)00176-3</ELocationID>
        <Abstract>
          <AbstractText>Amyotrophic lateral sclerosis (ALS) is characterized by motor neuron degeneration accompanied by aberrant accumulation and loss of function of the RNA-binding protein TDP43. Thus far, it remains unresolved to what extent TDP43 loss of function directly contributes to motor system dysfunction. Here, we employed gene editing to find whether the mouse ortholog of the TDP43-regulated gene STMN2 has an important function in maintaining the motor system. Both mosaic founders and homozygous loss-of-function Stmn2 mice exhibited neuromuscular junction denervation and fragmentation, resulting in muscle atrophy and impaired motor behavior, accompanied by an imbalance in neuronal microtubule dynamics in the spinal cord. The introduction of human STMN2 through BAC transgenesis was sufficient to rescue the motor phenotypes observed in Stmn2 mutant mice. Collectively, our results demonstrate that disrupting the ortholog of a single TDP43-regulated RNA is sufficient to cause substantial motor dysfunction, indicating that disruption of TDP43 function is likely a contributor to ALS.</AbstractText>
          <CopyrightInformation>Copyright © 2022 Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Guerra San Juan</LastName>
            <ForeName>Irune</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA; Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Harvard Stem Cell Institute, Harvard University, Cambridge, MA 02138, USA; Department of Functional Genomics, Center for Neurogenomics and Cognitive Research, Vrije Universiteit Amsterdam, 1081 HV Amsterdam, the Netherlands; Human Genetics, Amsterdam University Medical Center, 1081 HV Amsterdam, the Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nash</LastName>
            <ForeName>Leslie A</ForeName>
            <Initials>LA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA; Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Harvard Stem Cell Institute, Harvard University, Cambridge, MA 02138, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Smith</LastName>
            <ForeName>Kevin S</ForeName>
            <Initials>KS</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA; Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Harvard Stem Cell Institute, Harvard University, Cambridge, MA 02138, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Leyton-Jaimes</LastName>
            <ForeName>Marcel F</ForeName>
            <Initials>MF</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA; Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Harvard Stem Cell Institute, Harvard University, Cambridge, MA 02138, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Qian</LastName>
            <ForeName>Menglu</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA; Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Harvard Stem Cell Institute, Harvard University, Cambridge, MA 02138, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Klim</LastName>
            <ForeName>Joseph R</ForeName>
            <Initials>JR</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA; Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Harvard Stem Cell Institute, Harvard University, Cambridge, MA 02138, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Limone</LastName>
            <ForeName>Francesco</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA; Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Harvard Stem Cell Institute, Harvard University, Cambridge, MA 02138, USA; Leiden University Medical Center, 2333 ZA Leiden, the Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dorr</LastName>
            <ForeName>Alexander B</ForeName>
            <Initials>AB</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA; Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Harvard Stem Cell Institute, Harvard University, Cambridge, MA 02138, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Couto</LastName>
            <ForeName>Alexander</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA; Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Harvard Stem Cell Institute, Harvard University, Cambridge, MA 02138, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pintacuda</LastName>
            <ForeName>Greta</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Joseph</LastName>
            <ForeName>Brian J</ForeName>
            <Initials>BJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA; Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Harvard Stem Cell Institute, Harvard University, Cambridge, MA 02138, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Whisenant</LastName>
            <ForeName>D Eric</ForeName>
            <Initials>DE</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Noble</LastName>
            <ForeName>Caroline</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Melnik</LastName>
            <ForeName>Veronika</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Potter</LastName>
            <ForeName>Deirdre</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Holmes</LastName>
            <ForeName>Amie</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Burberry</LastName>
            <ForeName>Aaron</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA; Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Harvard Stem Cell Institute, Harvard University, Cambridge, MA 02138, USA; Department of Pathology, Case Western Reserve University, Cleveland, OH 44106, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Verhage</LastName>
            <ForeName>Matthijs</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Functional Genomics, Center for Neurogenomics and Cognitive Research, Vrije Universiteit Amsterdam, 1081 HV Amsterdam, the Netherlands; Human Genetics, Amsterdam University Medical Center, 1081 HV Amsterdam, the Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Eggan</LastName>
            <ForeName>Kevin</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA; Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Harvard Stem Cell Institute, Harvard University, Cambridge, MA 02138, USA. Electronic address: kevin.eggan@bmrn.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>K99 AG057808</GrantID>
            <Acronym>AG</Acronym>
            <Agency>NIA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 NS089742</GrantID>
            <Acronym>NS</Acronym>
            <Agency>NINDS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>15</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Neuron</MedlineTA>
        <NlmUniqueID>8809320</NlmUniqueID>
        <ISSNLinking>0896-6273</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D050777">Stathmin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C512849">Stmn2 protein, mouse</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006720" MajorTopicYN="N">Homozygote</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009469" MajorTopicYN="N">Neuromuscular Junction</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050777" MajorTopicYN="N">Stathmin</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">ALS</Keyword>
        <Keyword MajorTopicYN="N">CRISPR</Keyword>
        <Keyword MajorTopicYN="N">SCG10</Keyword>
        <Keyword MajorTopicYN="N">TARDBP</Keyword>
        <Keyword MajorTopicYN="N">TDP43</Keyword>
        <Keyword MajorTopicYN="N">microtubules</Keyword>
        <Keyword MajorTopicYN="N">motor neuron</Keyword>
        <Keyword MajorTopicYN="N">motor neuropathy</Keyword>
        <Keyword MajorTopicYN="N">neuromuscular junction</Keyword>
        <Keyword MajorTopicYN="N">stathmin 2</Keyword>
      </KeywordList>
      <CoiStatement>Declaration of interests K.E. is a cofounder of Q-State Biosciences, Quralis, and Enclear Therapies and currently head of research and early development at BioMarin Pharmaceutical. J.R.K. is an employee of Faze Medicines and a shareholder in Faze Medicines and QurAlis. K.E., I.G.S.J., J.R.K., and F.L. are authors on a pending patent that describes methods and compositions for restoring STMN2 levels (WO/2020/150290). K.E. is an author on a pending patent that describes compounds and methods for treating neurodegenerative diseases (WO2020107037).</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pmc-release">
          <Year>2023</Year>
          <Month>5</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>16</Day>
          <Hour>20</Hour>
          <Minute>5</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35294901</ArticleId>
        <ArticleId IdType="mid">NIHMS1791539</ArticleId>
        <ArticleId IdType="pmc">PMC9119928</ArticleId>
        <ArticleId IdType="doi">10.1016/j.neuron.2022.02.011</ArticleId>
        <ArticleId IdType="pii">S0896-6273(22)00176-3</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Al-Chalabi A, Calvo A, Chio A, Colville S, Ellis CM, Hardiman O, Heverin M, Howard RS, Huisman MHB, Keren N, et al. (2014). Analysis of amyotrophic lateral sclerosis as a multistep process: a population-based modelling study.
Lancet Neurol
13, 1108–1113. 10.1016/S14744422(14)70219-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S14744422(14)70219-4</ArticleId>
            <ArticleId IdType="pmc">PMC4197338</ArticleId>
            <ArticleId IdType="pubmed">25300936</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alami NH, Smith RB, Carrasco MA, Williams LA, Winborn CS, Han SSW, Kiskinis E, Winborn B, Freibaum BD, Kanagaraj A, et al. (2014). Axonal transport of TDP-43 mRNA granules is impaired by ALS-causing mutations.
Neuron
81, 536–543. 10.1016/j.neuron.2013.12.018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuron.2013.12.018</ArticleId>
            <ArticleId IdType="pmc">PMC3939050</ArticleId>
            <ArticleId IdType="pubmed">24507191</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arnold ES, Ling SC, Huelga SC, Lagier-Tourenne C, Polymenidou M, Ditsworth D, Kordasiewicz HB, McAlonis-Downes M, Platoshyn O, Parone PA, et al. (2013). ALS-linked TDP-43 mutations produce aberrant RNA splicing and adult-onset motor neuron disease without aggregation or loss of nuclear TDP-43.
Proceedings of the National Academy of Sciences of the United States of America
110, E736–745. 10.1073/pnas.1222809110</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1222809110</ArticleId>
            <ArticleId IdType="pmc">PMC3581922</ArticleId>
            <ArticleId IdType="pubmed">23382207</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ash PEA, Zhang Y-J, Roberts CM, Saldi T, Hutter H, Buratti E, Petrucelli L, and Link CD (2010). Neurotoxic effects of TDP-43 overexpression in C. elegans.
Human molecular genetics
19, 3206–3218. 10.1093/hmg/ddq230.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/hmg/ddq230</ArticleId>
            <ArticleId IdType="pmc">PMC2908471</ArticleId>
            <ArticleId IdType="pubmed">20530643</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Balice-Gordon RJ, and Lichtman JW (1990). In vivo visualization of the growth of pre- and postsynaptic elements of neuromuscular junctions in the mouse.
J Neurosci
10(3), 894–908. 10.1523/JNEUROSCI.10-03-00894.1990</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.10-03-00894.1990</ArticleId>
            <ArticleId IdType="pmc">PMC6570117</ArticleId>
            <ArticleId IdType="pubmed">2156964</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barmada SJ, Skibinski G, Korb E, Rao EJ, Wu JY, and Finkbeiner S (2010). Cytoplasmic mislocalization of TDP-43 is toxic to neurons and enhanced by a mutation associated with familial amyotrophic lateral sclerosis.
J Neurosci
30, 639–649. 10.1523/JNEUROSCI.4988-09.2010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.4988-09.2010</ArticleId>
            <ArticleId IdType="pmc">PMC2821110</ArticleId>
            <ArticleId IdType="pubmed">20071528</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blum JA, Klemm S, Shadrach JL, Guttenplan KA, Nakayama L, Kathiria A, Hoang PT, Gautier O, Kaltschmidt JA, Greenleaf WJ, et al. (2021). Single-cell transcriptomic analysis of the adult mouse spinal cord reveals molecular diversity of autonomic and skeletal motor neurons.
Nature Neuroscience
24, 572–583. 10.1038/s41593-020-00795-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41593-020-00795-0</ArticleId>
            <ArticleId IdType="pmc">PMC8016743</ArticleId>
            <ArticleId IdType="pubmed">33589834</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Briese M, Saal-Bauernschubert L, Lüningschrör P, Moradi M, Dombert B, Surrey V, Appenzeller S, Deng C, Jablonka S, and Sendtner M (2020). Loss of Tdp-43 disrupts the axonal transcriptome of motoneurons accompanied by impaired axonal translation and mitochondria function.
Acta Neuropathol Commun
8, 116. 10.1186/s40478-020-00987-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40478-020-00987-6</ArticleId>
            <ArticleId IdType="pmc">PMC7379803</ArticleId>
            <ArticleId IdType="pubmed">32709255</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brinkman EK, Chen T, Amendola M, and van Steensel B (2014). Easy quantitative assessment of genome editing by sequence trace decomposition.
Nucleic Acids Res
42, e168–e168. 10.1093/nar/gku936.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/nar/gku936</ArticleId>
            <ArticleId IdType="pmc">PMC4267669</ArticleId>
            <ArticleId IdType="pubmed">25300484</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burberry A, Suzuki N, Wang J-Y, Moccia R, Mordes DA, Stewart MH, Suzuki-Uematsu S, Ghosh S, Singh A, Merkle FT, et al. (2016). Loss-of-function mutations in the C9ORF72 mouse ortholog cause fatal autoimmune disease.
Sci Transl Med
8, 347ra393–347ra393. 10.1126/scitranslmed.aaf6038.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.aaf6038</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burberry A, Wells MF, Limone F, Couto A, Smith KS, Keaney J, Gillet G, van Gastel N, Wang JY, Pietilainen O, et al. (2020). C9orf72 suppresses systemic and neural inflammation induced by gut bacteria.
Nature
582, 89–94. 10.1038/s41586-020-2288-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-020-2288-7</ArticleId>
            <ArticleId IdType="pmc">PMC7416879</ArticleId>
            <ArticleId IdType="pubmed">32483373</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cappello V, and Francolini M (2017). Neuromuscular Junction Dismantling in Amyotrophic Lateral Sclerosis.
Int J Mol Sci
18, 2092. 10.3390/ijms18102092.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms18102092</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Charbaut E, Curmi PA, Ozon S, Lachkar S, Redeker V, and Sobel A (2001). Stathmin family proteins display specific molecular and tubulin binding properties.
The Journal of biological chemistry
276, 16146–16154. 10.1074/jbc.M010637200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M010637200</ArticleId>
            <ArticleId IdType="pubmed">11278715</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chauvin S, and Sobel A (2015). Neuronal stathmins: a family of phosphoproteins cooperating for neuronal development, plasticity and regeneration.
Progress in neurobiology
126, 1–18. 10.1016/j.pneurobio.2014.09.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pneurobio.2014.09.002</ArticleId>
            <ArticleId IdType="pubmed">25449700</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Corey DR (2017). Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy.
Nature neuroscience
20, 497–499. 10.1038/nn.4508.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nn.4508</ArticleId>
            <ArticleId IdType="pubmed">28192393</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fallini C, Bassell GJ, and Rossoll W (2012). The ALS disease protein TDP-43 is actively transported in motor neuron axons and regulates axon outgrowth.
Human molecular genetics
21, 3703–3718. 10.1093/hmg/dds205.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/hmg/dds205</ArticleId>
            <ArticleId IdType="pmc">PMC3406762</ArticleId>
            <ArticleId IdType="pubmed">22641816</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feneberg E, Gray E, Ansorge O, Talbot K, and Turner MR (2018). Towards a TDP-43-Based Biomarker for ALS and FTLD.
Mol Neurobiol
55, 7789–7801. 10.1007/s12035-018-0947-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12035-018-0947-6</ArticleId>
            <ArticleId IdType="pmc">PMC6132775</ArticleId>
            <ArticleId IdType="pubmed">29460270</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fischer LR, Culver DG, Tennant P, Davis AA, Wang M, Castellano-Sanchez A, Khan J, Polak MA, and Glass JD (2004). Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man.
Experimental Neurology
185, 232–240. 10.1016/j.expneurol.2003.10.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.expneurol.2003.10.004</ArticleId>
            <ArticleId IdType="pubmed">14736504</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Folker ES, and Baylies MK (2013). Nuclear positioning in muscle development and disease.
Front Physiol
4, 363-363. 10.3389/fphys.2013.00363.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fphys.2013.00363</ArticleId>
            <ArticleId IdType="pmc">PMC3859928</ArticleId>
            <ArticleId IdType="pubmed">24376424</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Foust KD, Nurre E, Montgomery CL, Hernandez A, Chan CM, and Kaspar BK (2009). Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes.
Nat Biotechnol
27, 5965. 10.1038/nbt.1515.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nbt.1515</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fratta P, Sivakumar P, Humphrey J, Lo K, Ricketts T, Oliveira H, Brito-Armas JM, Kalmar B, Ule A, Yu Y, et al. (2018). Mice with endogenous TDP-43 mutations exhibit gain of splicing function and characteristics of amyotrophic lateral sclerosis.
The EMBO journal
37. 10.15252/embj.201798684.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.15252/embj.201798684</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frey D, Schneider C, Xu L, Borg J, Spooren W, and Caroni P (2000). Early and selective loss of neuromuscular synapse subtypes with low sprouting competence in motoneuron diseases.
J Neurosci
20, 2534–2542. 10.1523/JNEUROSCI.20-07-02534.2000.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.20-07-02534.2000</ArticleId>
            <ArticleId IdType="pmc">PMC6772256</ArticleId>
            <ArticleId IdType="pubmed">10729333</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Geisler S, Doan RA, Strickland A, Huang X, Milbrandt J, and DiAntonio A (2016). Prevention of vincristine-induced peripheral neuropathy by genetic deletion of SARM1 in mice.
Brain
139, 3092–3108. 10.1093/brain/aww251.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/aww251</ArticleId>
            <ArticleId IdType="pmc">PMC5840884</ArticleId>
            <ArticleId IdType="pubmed">27797810</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giordana MT, Piccinini M, Grifoni S, De Marco G, Vercellino M, Magistrello M, Pellerino A, Buccinnà B, Lupino E, and Rinaudo MT (2010). TDP-43 redistribution is an early event in sporadic amyotrophic lateral sclerosis.
Brain Pathol
20, 351–360. 10.1111/j.1750-3639.2009.00284.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1750-3639.2009.00284.x</ArticleId>
            <ArticleId IdType="pmc">PMC8094784</ArticleId>
            <ArticleId IdType="pubmed">19338576</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Glass CK, Saijo K, Winner B, Marchetto MC, and Gage FH (2010). Mechanisms underlying inflammation in neurodegeneration.
Cell
140, 918–934. 10.1016/j.cell.2010.02.016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2010.02.016</ArticleId>
            <ArticleId IdType="pmc">PMC2873093</ArticleId>
            <ArticleId IdType="pubmed">20303880</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gonzalez-Freire M, de Cabo R, Studenski SA, and Ferrucci L (2014). The Neuromuscular Junction: Aging at the Crossroad between Nerves and Muscle.
Front Aging Neurosci
6, 208–208. 10.3389/fnagi.2014.00208.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fnagi.2014.00208</ArticleId>
            <ArticleId IdType="pmc">PMC4127816</ArticleId>
            <ArticleId IdType="pubmed">25157231</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Graf ER, Heerssen HM, Wright CM, Davis GW, and DiAntonio A (2011). Stathmin is required for stability of the Drosophila neuromuscular junction.
J Neurosci
31, 15026–15034. 10.1523/JNEUROSCI.2024-11.2011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.2024-11.2011</ArticleId>
            <ArticleId IdType="pmc">PMC3207242</ArticleId>
            <ArticleId IdType="pubmed">22016536</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hergesheimer RC, Chami AA, de Assis DR, Vourc’h P, Andres CR, Corcia P, Lanznaster D, and Blasco H (2019). The debated toxic role of aggregated TDP-43 in amyotrophic lateral sclerosis: a resolution in sight?
Brain
142, 1176–1194. 10.1093/brain/awz078.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awz078</ArticleId>
            <ArticleId IdType="pmc">PMC6487324</ArticleId>
            <ArticleId IdType="pubmed">30938443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Highley JR, Kirby J, Jansweijer JA, Webb PS, Hewamadduma CA, Heath PR, Higginbottom A, Raman R, Ferraiuolo L, Cooper-Knock J, et al. (2014). Loss of nuclear TDP-43 in amyotrophic lateral sclerosis (ALS) causes altered expression of splicing machinery and widespread dysregulation of RNA splicing in motor neurones.
Neuropathology and Applied Neurobiology
40, 670–685. 10.1111/nan.12148.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/nan.12148</ArticleId>
            <ArticleId IdType="pubmed">24750229</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang C, Tong J, Bi F, Zhou H, and Xia XG (2012). Mutant TDP-43 in motor neurons promotes the onset and progression of ALS in rats.
The Journal of clinical investigation
122, 107–118. 10.1172/JCI59130.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI59130</ArticleId>
            <ArticleId IdType="pmc">PMC3248298</ArticleId>
            <ArticleId IdType="pubmed">22156203</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Humphrey J, Emmett W, Fratta P, Isaacs AM, and Plagnol V (2017). Quantitative analysis of cryptic splicing associated with TDP-43 depletion.
BMC Med Genomics
10, 38-38. 10.1186/s12920-017-0274-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12920-017-0274-1</ArticleId>
            <ArticleId IdType="pmc">PMC5446763</ArticleId>
            <ArticleId IdType="pubmed">28549443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Igaz LM, Kwong LK, Lee EB, Chen-Plotkin A, Swanson E, Unger T, Malunda J, Xu Y, Winton MJ, Trojanowski JQ, et al. (2011). Dysregulation of the ALS-associated gene TDP-43 leads to neuronal death and degeneration in mice.
The Journal of clinical investigation
121, 726–738.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3026736</ArticleId>
            <ArticleId IdType="pubmed">21206091</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kanning KC, Kaplan A, and Henderson CE (2010). Motor neuron diversity in development and disease.
Annual review of neuroscience
33, 409–440. 10.1146/annurev.neuro.051508.135722.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev.neuro.051508.135722</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klim JR, Pintacuda G, Nash LA, Guerra San Juan I, and Eggan K (2021). Connecting TDP-43 Pathology with Neuropathy.
Trends in neurosciences
44, 424–440. 10.1016/j.tins.2021.02.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tins.2021.02.008</ArticleId>
            <ArticleId IdType="pubmed">33832769</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klim JR, Williams LA, Limone F, Guerra San Juan I, Davis-Dusenbery BN, Mordes DA, Burberry A, Steinbaugh MJ, Gamage KK, Kirchner R, et al. (2019). ALS-implicated protein TDP-43 sustains levels of STMN2, a mediator of motor neuron growth and repair.
Nature neuroscience
22, 167–179. 10.1038/s41593-018-0300-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41593-018-0300-4</ArticleId>
            <ArticleId IdType="pmc">PMC7153761</ArticleId>
            <ArticleId IdType="pubmed">30643292</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lall D, and Baloh RH (2017). Microglia and C9orf72 in neuroinflammation and ALS and frontotemporal dementia.
The Journal of clinical investigation
127, 3250–3258. 10.1172/JCI90607.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI90607</ArticleId>
            <ArticleId IdType="pmc">PMC5669558</ArticleId>
            <ArticleId IdType="pubmed">28737506</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liedtke W, Leman EE, Fyffe REW, Raine CS, and Schubart UK (2002). Stathmin-deficient mice develop an age-dependent axonopathy of the central and peripheral nervous systems.
Am J Pathol
160, 469–480. 10.1016/S0002-9440(10)64866-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0002-9440(10)64866-3</ArticleId>
            <ArticleId IdType="pmc">PMC1850667</ArticleId>
            <ArticleId IdType="pubmed">11839567</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Limone F, Mitchell JM, San Juan IG, Smith JLM, Raghunathan K, Couto A, Ghosh SD, Meyer D, Mello CJ, Nemesh J, et al. (2022). Efficient generation of lower induced Motor Neurons by coupling Ngn2 expression with developmental cues.
bioRxiv, 2022.2001.2012.476020.
10.1101/2022.01.12.476020</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/2022.01.12.476020</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin M-J, and Lee S-J (2016). Stathmin-like 4 is critical for the maintenance of neural progenitor cells in dorsal midbrain of zebrafish larvae.
Scientific Reports
6, 36188. 10.1038/srep36188.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/srep36188</ArticleId>
            <ArticleId IdType="pmc">PMC5098158</ArticleId>
            <ArticleId IdType="pubmed">27819330</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ling S-C, Albuquerque CP, Han JS, Lagier-Tourenne C, Tokunaga S, Zhou H, and Cleveland DW (2010). ALS-associated mutations in TDP-43 increase its stability and promote TDP-43 complexes with FUS/TLS.
Proceedings of the National Academy of Sciences
107, 13318–13323. 10.1073/pnas.1008227107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1008227107</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McNeill TH, Mori N, and Cheng HW (1999). Differential regulation of the growth-associated proteins, GAP-43 and SCG-10, in response to unilateral cortical ablation in adult rats.
Neuroscience
90, 1349–1360. 10.1016/s0306-4522(98)00482-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s0306-4522(98)00482-5</ArticleId>
            <ArticleId IdType="pubmed">10338302</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Melamed Z, Lopez-Erauskin J, Baughn MW, Zhang O, Drenner K, Sun Y, Freyermuth F, McMahon MA, Beccari MS, Artates JW, et al. (2019). Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration.
Nature neuroscience
22, 180–190. 10.1038/s41593-018-0293-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41593-018-0293-z</ArticleId>
            <ArticleId IdType="pmc">PMC6348009</ArticleId>
            <ArticleId IdType="pubmed">30643298</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meyer K, Ferraiuolo L, Schmelzer L, Braun L, McGovern V, Likhite S, Michels O, Govoni A, Fitzgerald J, Morales P, et al. (2015). Improving single injection CSF delivery of AAV9-mediated gene therapy for SMA: a dose-response study in mice and nonhuman primates.
Mol Ther
23, 477–487. 10.1038/mt.2014.210.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/mt.2014.210</ArticleId>
            <ArticleId IdType="pmc">PMC4351452</ArticleId>
            <ArticleId IdType="pubmed">25358252</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mitchell JC, Constable R, So E, Vance C, Scotter E, Glover L, Hortobagyi T, Arnold ES, Ling SC, McAlonis M, et al. (2015). Wild type human TDP-43 potentiates ALS-linked mutant TDP-43 driven progressive motor and cortical neuron degeneration with pathological features of ALS.
Acta Neuropathol Commun
3, 36–36. 10.1186/s40478-015-0212-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40478-015-0212-4</ArticleId>
            <ArticleId IdType="pmc">PMC4479086</ArticleId>
            <ArticleId IdType="pubmed">26108367</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moisse K, Mepham J, Volkening K, Welch I, Hill T, and Strong MJ (2009). Cytosolic TDP-43 expression following axotomy is associated with caspase 3 activation in NFL−/− mice: support for a role for TDP-43 in the physiological response to neuronal injury.
Brain research
1296, 176–186. 10.1016/j.brainres.2009.07.023</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.brainres.2009.07.023</ArticleId>
            <ArticleId IdType="pubmed">19619516</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morii H, Shiraishi-Yamaguchi Y, and Mori N (2006). SCG10, a microtubule destabilizing factor, stimulates the neurite outgrowth by modulating microtubule dynamics in rat hippocampal primary cultured neurons.
Journal of Neurobiology
66, 1101–1114. 10.1002/neu.20295.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/neu.20295</ArticleId>
            <ArticleId IdType="pubmed">16838365</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morisaki Y, Niikura M, Watanabe M, Onishi K, Tanabe S, Moriwaki Y, Okuda T, Ohara S, Murayama S, Takao M, et al. (2016). Selective Expression of Osteopontin in ALS-resistant Motor Neurons is a Critical Determinant of Late Phase Neurodegeneration Mediated by Matrix Metalloproteinase-9.
Scientific reports
6, 27354. 10.1038/srep27354.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/srep27354</ArticleId>
            <ArticleId IdType="pmc">PMC4893611</ArticleId>
            <ArticleId IdType="pubmed">27264390</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM, et al. (2006). Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis.
Science (New York, NY)
314, 130–133. 10.1126/science.1134108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1134108</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nguyen TB, Prabhu VV, Piao YH, Oh YE, Zahra RF, and Chung YC (2019). Effects of Stathmin 1 Gene Knockout on Behaviors and Dopaminergic Markers in Mice Exposed to Social Defeat Stress.
Brain sciences
9. 0.3390/brainsci9090215.</Citation>
        </Reference>
        <Reference>
          <Citation>Nijssen J, Comley LH, and Hedlund E (2017). Motor neuron vulnerability and resistance in amyotrophic lateral sclerosis.
Acta Neuropathologica
133, 863–885. 10.1007/s00401-017-1708-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00401-017-1708-8</ArticleId>
            <ArticleId IdType="pmc">PMC5427160</ArticleId>
            <ArticleId IdType="pubmed">28409282</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oishi T, Higo N, Matsuda K, and Hayashi M (2002). Expression of super cervical ganglion-10 (SCG10) mRNA in the monkey cerebral cortex during postnatal development.
Neurosci Lett
323, 199–202. 10.1016/s0304-3940(02)00142-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s0304-3940(02)00142-8</ArticleId>
            <ArticleId IdType="pubmed">11959419</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Okazaki T, Yoshida BN, Avraham KB, Wang H, Wuenschell CW, Jenkins NA, Copeland NG, Anderson DJ, and Mori N (1993). Molecular diversity of the SCG10/stathmin gene family in the mouse.
Genomics
18, 360–373. 10.1006/geno.1993.1477.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1006/geno.1993.1477</ArticleId>
            <ArticleId IdType="pubmed">8288240</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Olesen MN, Wuolikainen A, Nilsson AC, Wirenfeldt M, Forsberg K, Madsen JS, Lillevang ST, Brandslund I, Andersen PM, and Asgari N (2020). Inflammatory profiles relate to survival in subtypes of amyotrophic lateral sclerosis.
Neurology - Neuroimmunology Neuroinflammation
7, e697. 10.1212/NXI.0000000000000697.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000697</ArticleId>
            <ArticleId IdType="pmc">PMC7136052</ArticleId>
            <ArticleId IdType="pubmed">32123048</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ozon S, Byk T, and Sobel A (1998). SCLIP: a novel SCG10-like protein of the stathmin family expressed in the nervous system.
J Neurochem
70, 2386–2396. 10.1046/j.1471-4159.1998.70062386.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1046/j.1471-4159.1998.70062386.x</ArticleId>
            <ArticleId IdType="pubmed">9603203</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patel T, Hammelman J, Closser M, Gifford DK, and Wichterle H (2021). General and cell-typespecific aspects of the motor neuron maturation transcriptional program.
bioRxiv, 2021.2003.2005.434185.
10.1101/2021.03.05.434185.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/2021.03.05.434185</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Philips T, and Robberecht W (2011). Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease.
The Lancet Neurology
10, 253–263. 10.1016/S1474-4422(11)70015-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(11)70015-1</ArticleId>
            <ArticleId IdType="pubmed">21349440</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prasad A, Bharathi V, Sivalingam V, Girdhar A, and Patel BK (2019). Molecular Mechanisms of TDP-43 Misfolding and Pathology in Amyotrophic Lateral Sclerosis.
Frontiers in molecular neuroscience
12, 25–25. 10.3389/fnmol.2019.00025.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fnmol.2019.00025</ArticleId>
            <ArticleId IdType="pmc">PMC6382748</ArticleId>
            <ArticleId IdType="pubmed">30837838</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prudencio M, Humphrey J, Pickles S, Brown AL, Hill SE, Kachergus J, Shi J, Heckman M, Spiegel M, Cook C, et al. (2020). Truncated stathmin-2 is a marker of TDP-43 pathology in frontotemporal dementia.
The Journal of clinical investigation
10.1172/JCI139741.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI139741</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pun S, Santos AF, Saxena S, Xu L, and Caroni P (2006). Selective vulnerability and pruning of phasic motoneuron axons in motoneuron disease alleviated by CNTF.
Nature neuroscience
9, 408–419. 10.1038/nn1653.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nn1653</ArticleId>
            <ArticleId IdType="pubmed">16474388</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Riederer BM, Pellier V, Antonsson B, Di Paolo G, Stimpson SA, Lütjens R, Catsicas S, and Grenningloh G (1997). Regulation of microtubule dynamics by the neuronal growth-associated protein SCG10.
Proceedings of the National Academy of Sciences of the United States of America
94, 741–745. 10.1073/pnas.94.2.741</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.94.2.741</ArticleId>
            <ArticleId IdType="pmc">PMC19584</ArticleId>
            <ArticleId IdType="pubmed">9012855</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roman W, and Gomes ER (2018). Nuclear positioning in skeletal muscle.
Seminars in Cell &amp; Developmental Biology
82, 51–56. 10.1016/j.semcdb.2017.11.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.semcdb.2017.11.005</ArticleId>
            <ArticleId IdType="pubmed">29241690</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sato T, Takeuchi S, Saito A, Ding W, Bamba H, Matsuura H, Hisa Y, Tooyama I, and Urushitani M (2009). Axonal ligation induces transient redistribution of TDP-43 in brainstem motor neurons.
Neuroscience
164, 1565–1578. 10.1016/j.neuroscience.2009.09.050.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuroscience.2009.09.050</ArticleId>
            <ArticleId IdType="pubmed">19782731</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shin JE, Geisler S, and DiAntonio A (2014). Dynamic regulation of SCG10 in regenerating axons after injury.
Exp Neurol
252, 1–11. 10.1016/j.expneurol.2013.11.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.expneurol.2013.11.007</ArticleId>
            <ArticleId IdType="pmc">PMC3947015</ArticleId>
            <ArticleId IdType="pubmed">24246279</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shin JE, Miller BR, Babetto E, Cho Y, Sasaki Y, Qayum S, Russler EV, Cavalli V, Milbrandt J, and DiAntonio A (2012). SCG10 is a JNK target in the axonal degeneration pathway.
Proceedings of the National Academy of Sciences of the United States of America
109, E3696–E3705. 10.1073/pnas.1216204109.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1216204109</ArticleId>
            <ArticleId IdType="pmc">PMC3535671</ArticleId>
            <ArticleId IdType="pubmed">23188802</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sugiura Y, and Mori N (1995). SCG10 expresses growth-associated manner in developing rat brain, but shows a different pattern to p19/stathmin or GAP-43.
Brain Res Dev Brain Res
90, 73–91. 10.1016/0165243806(96)83488-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0165243806(96)83488-2</ArticleId>
            <ArticleId IdType="pubmed">8719331</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Theunissen F, Anderton RS, Mastaglia FL, Flynn LL, Winter SJ, James I, Bedlack R, Hodgetts S, Fletcher S, Wilton SD, et al. (2021). Novel STMN2 Variant Linked to Amyotrophic Lateral Sclerosis Risk and Clinical Phenotype.
Frontiers in Aging Neuroscience
13. 10.3389/fnagi.2021.658226.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fnagi.2021.658226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tian W, Czopka T, and López-Schier H (2020). Systemic loss of Sarm1 protects Schwann cells from chemotoxicity by delaying axon degeneration.
Communications biology
3, 49. 10.1038/s42003-0200776-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s42003-0200776-9</ArticleId>
            <ArticleId IdType="pmc">PMC6992705</ArticleId>
            <ArticleId IdType="pubmed">32001778</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Turkiew E, Falconer D, Reed N, and Höke A (2017). Deletion of Sarm1 gene is neuroprotective in two models of peripheral neuropathy.
Journal of the peripheral nervous system : JPNS
22, 162–171.10.1111/jns.12219.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jns.12219</ArticleId>
            <ArticleId IdType="pmc">PMC5585053</ArticleId>
            <ArticleId IdType="pubmed">28485482</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van de Willige D, Hoogenraad CC, and Akhmanova A (2016). Microtubule plus-end tracking proteins in neuronal development.
Cell Mol Life Sci
73, 2053–2077. 10.1007/s00018-016-2168-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00018-016-2168-3</ArticleId>
            <ArticleId IdType="pmc">PMC4834103</ArticleId>
            <ArticleId IdType="pubmed">26969328</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van Deerlin VM, Leverenz JB, Bekris LM, Bird TD, Yuan W, Elman LB, Clay D, Wood EM, Chen-Plotkin AS, Martinez-Lage M, et al. (2008). TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis.
Lancet Neurol
7, 409–416. 10.1016/S1474-4422(08)70071-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(08)70071-1</ArticleId>
            <ArticleId IdType="pmc">PMC3546119</ArticleId>
            <ArticleId IdType="pubmed">18396105</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vanden Broeck L, Callaerts P, and Dermaut B (2014). TDP-43-mediated neurodegeneration: towards a loss-of-function hypothesis?
Trends in molecular medicine
20, 66–71. 10.1016/j.molmed.2013.11.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molmed.2013.11.003</ArticleId>
            <ArticleId IdType="pubmed">24355761</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wils H, Kleinberger G, Janssens J, Pereson S, Joris G, Cuijt I, Smits V, Ceuterick-de Groote C, Van Broeckhoven C, and Kumar-Singh S (2010). TDP-43 transgenic mice develop spastic paralysis and neuronal inclusions characteristic of ALS and frontotemporal lobar degeneration.
Proceedings of the National Academy of Sciences of the United States of America
107, 3858–3863. 10.1073/pnas.0912417107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0912417107</ArticleId>
            <ArticleId IdType="pmc">PMC2840518</ArticleId>
            <ArticleId IdType="pubmed">20133711</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu Y-F, Gendron TF, Zhang Y-J, Lin W-L, D’Alton S, Sheng H, Casey MC, Tong J, Knight J, Yu X, et al. (2010). Wild-type human TDP-43 expression causes TDP-43 phosphorylation, mitochondrial aggregation, motor deficits, and early mortality in transgenic mice.
J Neurosci
30, 10851–10859. 10.1523/JNEUROSCI.1630-10.2010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.1630-10.2010</ArticleId>
            <ArticleId IdType="pmc">PMC3056148</ArticleId>
            <ArticleId IdType="pubmed">20702714</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang H, Wang H, and Jaenisch R (2014). Generating genetically modified mice using CRISPR/Casmediated genome engineering.
Nature Protocols
9, 1956–1968. 10.1016/j.cell.2013.08.022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2013.08.022</ArticleId>
            <ArticleId IdType="pubmed">25058643</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y, Pak C, Han Y, Ahlenius H, Zhang Z, Chanda S, Marro S, Patzke C, Acuna C, Covy J, et al. (2013). Rapid single-step induction of functional neurons from human pluripotent stem cells.
Neuron
78, 785–798. 10.1016/j.neuron.2013.05.029.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuron.2013.05.029</ArticleId>
            <ArticleId IdType="pmc">PMC3751803</ArticleId>
            <ArticleId IdType="pubmed">23764284</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
